365 Days of Progress In Skin Cancer

7.8K

views

23

authors

4

articles

365 Days of Progress In Skin Cancer

7.8K

views

23

authors

4

articles

Editors

2

Vladimir Spiegelman

Penn State Milton S. Hershey Medical Center

University of Alabama at Birmingham

Impact

About

“365 Days of Progress” is part of a wider series of Research Topics across Frontiers in Oncology, hosted by our Specialty Chief Editors, showcasing popular articles from 2021 igniting interest in the field.

This Research Topic aims to highlight the work featured and spark further discussion. The Skin Cancer field is continuously evolving, therefore we are seeking to understand developments and perspectives on articles that have attracted attention throughout the year.

We welcome Opinions, Perspectives, and Mini-Review article types to facilitate this discussion. We also welcome updated original data following the research featured in this collection. Please note only papers that are relevant and add a significant contribution to the discussion articles will be considered.

The chosen manuscripts are :

- Mucosal Melanoma: Pathological Evolution, Pathway Dependency and Targeted Therapy
- Decoding Melanoma Development and Progression: Identification of Therapeutic Vulnerabilities
- Cutaneous Melanoma Classification: The Importance of High-Throughput Genomic Technologies
- The WHO 2018 Classification of Cutaneous Melanocytic Neoplasms: Suggestions From Routine Practice
- Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy
- Multiplexed Immunohistochemistry and Digital Pathology as the Foundation for Next-Generation Pathology in Melanoma: Methodological Comparison and Future Clinical Applications
- Beyond PD-1: The Next Frontier for Immunotherapy in Melanoma
- A Multi-Omics Analysis of Metastatic Melanoma Identifies a Germinal Center-Like Tumor Microenvironment in HLA-DR-Positive Tumor Areas

Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.

“365 Days of Progress” is part of a wider series of Research Topics across Frontiers in Oncology, hosted by our Specialty Chief Editors, showcasing popular articles from 2021 igniting interest in the field.

This Research Topic aims to highlight the work featured and spark further discussion. The Skin Cancer field is continuously evolving, therefore we are seeking to understand developments and perspectives on articles that have attracted attention throughout the year.

We welcome Opinions, Perspectives, and Mini-Review article types to facilitate this discussion. We also welcome updated original data following the research featured in this collection. Please note only papers that are relevant and add a significant contribution to the discussion articles will be considered.

The chosen manuscripts are :

- Mucosal Melanoma: Pathological Evolution, Pathway Dependency and Targeted Therapy
- Decoding Melanoma Development and Progression: Identification of Therapeutic Vulnerabilities
- Cutaneous Melanoma Classification: The Importance of High-Throughput Genomic Technologies
- The WHO 2018 Classification of Cutaneous Melanocytic Neoplasms: Suggestions From Routine Practice
- Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy
- Multiplexed Immunohistochemistry and Digital Pathology as the Foundation for Next-Generation Pathology in Melanoma: Methodological Comparison and Future Clinical Applications
- Beyond PD-1: The Next Frontier for Immunotherapy in Melanoma
- A Multi-Omics Analysis of Metastatic Melanoma Identifies a Germinal Center-Like Tumor Microenvironment in HLA-DR-Positive Tumor Areas

Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.

Share

Editors

Vladimir Spiegelman

Penn State Milton S. Hershey Medical Center

University of Alabama at Birmingham

Impact

7,768 Total views

5,457 Article views

2,118 Article downloads

193 Topic views

Published In

Journal Thumbnail

Frontiers in Oncology

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Suggest a topic